CD19 and neoplasm: In our prior study using the murine DOTA-antibody reporter DAbR1 and the probe [86Y]Y-AABD for in vivo tracking of 3x106 i.v. injected CD19 CAR-T cells in a subcutaneous high-burden CD19+ tumor model, we observed heterogeneously increased uptake at the tumor site below 1 %ID/g at 16 h post-tracer administration on day 10 post-T cell injection 14.